Esperion Therapeutics
ESPR
ESPR
163 hedge funds and large institutions have $1.11B invested in Esperion Therapeutics in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 58 increasing their positions, 41 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
8% less capital invested
Capital invested by funds: $1.2B → $1.11B (-$95.4M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
47% less call options, than puts
Call options by funds: $14M | Put options by funds: $26.5M
Holders
163
Holding in Top 10
6
Calls
$14M
Puts
$26.5M
Top Buyers
| 1 | +$8.72M | |
| 2 | +$7.14M | |
| 3 | +$7.13M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.78M |
| 5 |
Millennium Management
New York
|
+$6.65M |
Top Sellers
| 1 | -$10.1M | |
| 2 | -$9.03M | |
| 3 | -$9.02M | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.45M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.43M |